Skye Bioscience annual return on equity
2013
2021
2022
2024
2025
Skye Bioscience Return on Equity (ROE) Growth & History (SKYE)
Skye Bioscience's return on equity was −126.85% for fiscal 2025.
View full Skye Bioscience company overviewSkye Bioscience annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −126.85% | −46.37 pp |
| 2024 | 2024-12-31 | −80.48% | — |
| 2022 | 2022-12-31 | −1,364.20% | −1094.30 pp |
| 2021 | 2021-12-31 | −269.90% | — |
| 2013 · Oct 31 | 2013-10-31 | −6.20% | — |
Skye Bioscience quarterly return on equity
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −253.37% | −219.12 pp |
| Q1 2026 | 2026-03-31 | −86.16% | −68.73 pp |
| Q4 2025 | 2025-12-31 | −54.64% | −41.10 pp |
| Q3 2025 | 2025-09-30 | −33.34% | −28.09 pp |
| Q2 2025 | 2025-06-30 | −34.25% | −23.83 pp |
| Q1 2025 | 2025-03-31 | −17.43% | −4.35 pp |
| Q4 2024 | 2024-12-31 | −13.54% | — |
| Q3 2024 | 2024-09-30 | −5.25% | — |
| Q2 2024 | 2024-06-30 | −10.42% | — |
| Q1 2024 | 2024-03-31 | −13.08% | — |
| Q2 2022 | 2022-06-30 | −256.00% | −170.78 pp |
| Q1 2022 | 2022-03-31 | −68.88% | +78.63 pp |
| Q4 2021 | 2021-12-31 | −35.57% | +94.81 pp |
| Q3 2021 | 2021-09-30 | −34.64% | — |
| Q2 2021 | 2021-06-30 | −85.23% | — |
| Q1 2021 | 2021-03-31 | −147.50% | — |
| Q4 2020 | 2020-12-31 | −130.38% | — |
| Q3 2014 · Sep 30 | 2014-09-30 | −200.25% | — |
| Q2 2014 · Jul 31 | 2014-07-31 | 10.04% | +11.14 pp |
| Q1 2014 · Apr 30 | 2014-04-30 | −16.85% | −20.83 pp |
| Q3 2013 | 2013-07-31 | −1.09% | — |
| Q2 2013 | 2013-04-30 | 3.97% | — |
Skye Bioscience return on equity trends
Between the periods ended 2013-10-31 and 2025-12-31, Skye Bioscience's return on equity decreased from −6.20% to −126.85%, a change of −120.65 percentage points. The latest reported quarter, Q2 2026, shows −253.37%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Skye Bioscience source filings ↗